Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte to evaluate additional subcutaneous ...

With concerns over the competitiveness of its subcutaneous (SC) injection platform leading to a sharp decline in its stock ...

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets ...

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

Temporary Suspension of KOSPI Transfer Listing...Background of Staying Attracts Attention While Alteogen has faced share ...

People living with early Alzheimer’s disease can now begin treatment with Leqembi without setting foot in an infusion center.

All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -- Independent ...

The results of two phase 3 trials suggest that investigational drug bepirovirsen reduces HBsAg production, helping the immune ...

A new advanced body composition scan measures muscle, fat, and dangerous visceral fat, helping patients track health beyond the number on the scale.

All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety ...

Gilead Sciences, Inc. today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV ...

With War Secretary Pete Hegseth fueling a national conversation about testosterone, many men may wonder whether their own ...